This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on january 12, 2021.Upon further investigation of the reported event, the following information is new and/or changed: d4 (additional device information - added expiration date) d8 (device serviced by a third party) d10 (device availability - added date returned to manufacturer) g6 (indication that this is a follow-up report) h2 (follow-up due to additional information and device evaluation) h3 (device evaluated by manufacturer) h4 (device manufacture date) h6 (identification of evaluation codes 483, 2645, 4582, 10, 11, 3331, 3259, 4307) component code: 483 - manifold health effect - impact code: 2645 - no patient involvement health effect - clinical code: 4582 - no clinical signs, symptoms or conditions type of investigation #1:10 - testing of actual/suspected device type of investigation #2: 11 - testing of device from same lot/batch retained by manufacturer type of investigation #3: 3331 - analysis of production records investigation findings: 3259 - improper physical structure investigation conclusions: 4307 - cause traced to component failure the affected sample was inspected upon receipt confirming damage to the manifold.A representative retention sample was inspected for damage.No damage was observed on the unit, specifically on the manifold.All capiox units are 100% visually inspected at several points in the production process all available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|